Precision medicine oncology company, IDEAYA Biosciences, Inc., is pioneering the development of targeted therapeutics for patient populations through the use of molecular diagnostics. The company's product portfolio includes IDE397, a Phase II clinical trial methionine adenosyltransferase 2a inhibitor for solid tumor patients with methylthioadenosine phosphorylase gene deletions, and IDE196, a protein kinase C inhibitor in Phase I/II clinical trials for genetically defined cancers with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline covers synthetic lethality programs targeting tumor biomarkers based on genetic mutations and/or molecular signatures, including PARG inhibitor for patients with tumors, Pol Theta inhibitors for tumors with BRCA or other homologous recombination deficiency mutations, and WRN inhibitors for tumors with high microsatellite instability. The company boasts research collaborations with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, and a clinical trial collaboration and supply agreement with Pfizer Inc. for a Phase II/III study in metastatic uveal melanoma. Additionally, IDEAYA has formed a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was founded in 2015 and is headquartered in South San Francisco, California.